Perceived Burden of Respiratory Physiotherapy in People with Cystic Fibrosis Taking Elexacaftor-tezacaftor-ivacaftor Combination: a 1-year Observational Study

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2024 Mar 30

PMID 38554035

Authors

Chiara Blardone

Simone Gambazza

Alessandra Mariani

Rachele Galgani

Anna Brivio

Rita Maria Nobili

Carmela Rizza

Anna Luisa Tutino

Andrea Gramegna

Valeria Dacco

Martina Contarini

Francesco Blasi

Dario Laquintana

Affiliations

Soon will be listed here.

Abstract

Background: To limit the progression of disease, people with cystic fibrosis (pwCF) perform daily respiratory physiotherapy, which is perceived as the most burdensome routine in managing their condition. The elexacaftor-tezacaftor-ivacaftor (ETI) combination has changed respiratory management.

Objective: To investigate how the perceived treatment burden changed in 1 year of treatment with ETI.

Design: Prospective observational study.

Methods: questionnaires for the pwCF and for the caregivers of pwCF < 18 years were administered before the initiation of ETI therapy and then at 6-12 months. The Cystic Fibrosis Questionnaire-Revised (CFQ-R) and the Sinonasal Outcome Test (SNOT-22) were administered to explore disease-related symptoms and social limitations. The International Physical Activity Questionnaire was used to determine levels of physical activity. Mixed-effect models were fitted to explore whether the time engaged in respiratory physiotherapy changed during 1 year.

Results: The study included 47/184 pwCF aged 21.4 (5.7) years, who completed 1 year of ETI therapy. At 6 months, time on aerosol therapy was decreased by 2.5 (95% CI -32.9 to 27.8) min/day, time on airway clearance therapies (ACTs) was decreased by 8.8 (95% CI -25.9 to 8.3) min/day, and time for cleaning and disinfecting respiratory equipment was decreased by 10.6 (95% CI -26.5 to 5.3) min/day. At 1 year, gains in time saved were nearly 15 min/day on average. At 1 year, 5/47 (10.6%) pwCF reported that they had discontinued positive expiratory pressure mask.

Conclusion: PwCF on ETI may note less time engaged in their daily respiratory physiotherapy routine. Nonetheless, aerosol therapy, ACTs and maintaining respiratory equipment were still perceived as time-consuming daily activities.

Citing Articles

Psychosocial and mental health in cystic fibrosis in the modern era of care: time to evolve.

Harrigan M, Georgiopoulos A, Quittner A, Smith B, Douglas T BMJ Open Respir Res. 2025; 12(1).

PMID: 39929550 PMC: 11815457. DOI: 10.1136/bmjresp-2024-002606.

Exercise as an airway clearance technique (ExACT) is not simply physical activity.

Saynor Z, Urquhart D Ther Adv Respir Dis. 2024; 18:17534666241292502.

PMID: 39512159 PMC: 11544647. DOI: 10.1177/17534666241292502.

References

Gambazza S, Zuffo S . CPAP in cystic fibrosis: is it time to surrender yet?. Respir Care. 2013; 58(9):e116-7. DOI: 10.4187/respcare.02655. View

Saluzzo F, Riberi L, Messore B, Lore N, Esposito I, Bignamini E . CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis. Cells. 2022; 11(7). PMC: 8998122. DOI: 10.3390/cells11071243. View

Mozzanica F, Preti A, Gera R, Gallo S, Bulgheroni C, Bandi F . Cross-cultural adaptation and validation of the SNOT-22 into Italian. Eur Arch Otorhinolaryngol. 2016; 274(2):887-895. DOI: 10.1007/s00405-016-4313-x. View

Cameron R, Office D, Matthews J, Rowley M, Abbott J, Simmonds N . Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment Burden. Chest. 2022; 162(6):1241-1254. PMC: 9773229. DOI: 10.1016/j.chest.2022.07.008. View

Craig C, Marshall A, Sjostrom M, Bauman A, Booth M, Ainsworth B . International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35(8):1381-95. DOI: 10.1249/01.MSS.0000078924.61453.FB. View

Heijerman H, McKone E, Downey D, Van Braeckel E, Rowe S, Tullis E . Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Lancet. 2019; 394(10212):1940-1948. PMC: 7571408. DOI: 10.1016/S0140-6736(19)32597-8. View

Bishay L, Sawicki G . Strategies to optimize treatment adherence in adolescent patients with cystic fibrosis. Adolesc Health Med Ther. 2016; 7:117-124. PMC: 5085292. DOI: 10.2147/AHMT.S95637. View

Gambazza S, Ambrogi F, Carta F, Moroni L, Russo M, Brivio A . Lung clearance index to characterize clinical phenotypes of children and adolescents with cystic fibrosis. BMC Pulm Med. 2022; 22(1):122. PMC: 8976307. DOI: 10.1186/s12890-022-01903-5. View

von Elm E, Altman D, Egger M, Pocock S, Gotzsche P, Vandenbroucke J . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344-9. DOI: 10.1016/j.jclinepi.2007.11.008. View

10.

Barry P, Mall M, Alvarez A, Colombo C, de Winter-de Groot K, Fajac I . Triple Therapy for Cystic Fibrosis -Gating and -Residual Function Genotypes. N Engl J Med. 2021; 385(9):815-825. PMC: 8982185. DOI: 10.1056/NEJMoa2100665. View

11.

Almulhem M, Harnett N, Graham S, Haq I, Visram S, Ward C . Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals. BMJ Open Respir Res. 2022; 9(1). PMC: 9557266. DOI: 10.1136/bmjresp-2022-001420. View

12.

Hopkins C, Gillett S, Slack R, Lund V, Browne J . Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009; 34(5):447-54. DOI: 10.1111/j.1749-4486.2009.01995.x. View

13.

Quanjer P, Stanojevic S, Cole T, Baur X, Hall G, Culver B . Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012; 40(6):1324-43. PMC: 3786581. DOI: 10.1183/09031936.00080312. View

14.

Conway S, Balfour-Lynn I, De Rijcke K, Drevinek P, Foweraker J, Havermans T . European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. J Cyst Fibros. 2014; 13 Suppl 1:S3-22. PMC: 7105239. DOI: 10.1016/j.jcf.2014.03.009. View

15.

Quittner A, Buu A, Messer M, Modi A, Watrous M . Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005; 128(4):2347-54. DOI: 10.1378/chest.128.4.2347. View

16.

Rowbotham N, Smith S, Leighton P, Rayner O, Gathercole K, Elliott Z . The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax. 2017; 73(4):388-390. PMC: 5870449. DOI: 10.1136/thoraxjnl-2017-210473. View

17.

Mannocci A, Masala D, Mei D, Tribuzio A, Villari P, La Torre G . International Physical Activity Questionnaire for Adolescents (IPAQ A): reliability of an Italian version. Minerva Pediatr (Torino). 2018; 73(5):383-390. DOI: 10.23736/S2724-5276.16.04727-7. View

18.

Raywood E, Shannon H, Filipow N, Tanriver G, Stanojevic S, Kapoor K . Quantity and quality of airway clearance in children and young people with cystic fibrosis. J Cyst Fibros. 2022; 22(2):344-351. DOI: 10.1016/j.jcf.2022.09.008. View

19.

Rowbotham N, Daniels T . Airway clearance and exercise for people with cystic fibrosis: Balancing longevity with life. Pediatr Pulmonol. 2021; 57 Suppl 1:S50-S59. DOI: 10.1002/ppul.25734. View

20.

Eakin M, Bilderback A, Boyle M, Mogayzel P, Riekert K . Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011; 10(4):258-64. PMC: 3114200. DOI: 10.1016/j.jcf.2011.03.005. View